Mergers and Acquisitions
United Technologies Should Resume Its Advance When the Broad Market Stabilizes
Let's review the charts and indicators.
Biotech's Big Week Finds a Big Winner in Adaptimmune
The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.
What If Fitbit's Deal With Alphabet Doesn't Happen?
It's likely the deal goes through, but I don't believe that attempting to take advantage of FIT's current 11% discount is worth the risk.
2 Potential Targets as Biotech Acquisition Activity Heats Up
TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.
Making Sausage: How the Fitbit Deal Got Done
A document filed with the SEC reveals the behind-the-scenes competition between Alphabet and another suitor for the hand of the smartwatch maker.
Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
IAC's CFO Talks About Holding Onto ANGI and the Current M&A Environment
During a talk with TheStreet, CFO Glenn Schiffman talked about IAC's reasons for holding off on an ANGI Homeservices spinoff, as well as the differences between private and public valuations.
Foot Locker's Assets May Look Better Than Its Charts
Let's see whether FL is a good fit for investors right now.
Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not
We're seeing lots of companies snapping up their peers, and the market is applauding.
'Dance' With E*Trade as It Searches for a Partner
With the potential TD Ameritrade deal, clearly E*Trade will not be 'talking to Chuck.'
News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon
Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.
HP and Xerox? Not Such a Bad Idea
With Carl Icahn involved on both sides, we can expect him to lean heavily on both Boards to come to an agreement.
HP Has My Attention, but I'm Not Getting In Now
If tempted, don't forget HPQ will report the firm's fourth quarter performance next Tuesday.
HP Plays Hard to Get, but Charts Provide a Clearer Picture
HP's board of directors has rejected Xerox's takeover bid, but the door has not been closed on a potential combination.
Viacom's Charts Can't Divine Impact on Price Action of CBS Merger
Traders would do well to find another stock to trade right now.
I Still Like Housing, Just Not as Much as Before
After the strong run of homebuilders in 2019, the sector simply isn't as oversold as it was to start the year.
Trade Walgreens for the Same Reason It Might Go Private
I see upside back to above $70 regardless of whether the company gets taken private.
CBS Earnings Lead to 'Interesting' Questions - And What About the Stock?
Things that make you go hmmm ahead of the Viacom merger.
CBS Charts Eye a Potential Rise in Its Shares
The media giant's technical signals hint at an upside move in its stock.
First Horizon National Can Move Higher in the Months Ahead
FHN announced earlier this week it is merging with Iberia Bank.
Jim Cramer: Stop Speculating on Deals
I'm all in favor of mergers and acquisitions -- the more we get, the higher the stock market goes -- but I am not in favor of making conclusions based on tips about deals.
Why a Walgreens Buyout Could Stink for Corporate Bond Investors
Reports of two potentially major buyouts show the risks of late-cycle corporate bond investing.
That's It for Fitbit As I Take the Money and Run
Let others wait and see if someone comes in with a better offer than Alphabet's bid for Fitbit; this value investor is taking his profit and leaving the table.
3 Stocks to Consider Amid Possible Consolidation in Luxury Retail
The buyout offer for Tiffany & Co. from Louis Vuitton's parent could spark more deals; this trio of sagging stocks could make for targets.
Fitbit Shares Shape Up on Reports of Offer From Alphabet
The maker of wearable fitness devices has seen its stock sprint higher on the buyout news after languishing this summer near multi-year lows.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Big Biotech Receives Some Needed Shots in the Arm
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
Raytheon Could Rally to the $230 Area in the Months Ahead - How to Buy It Now
Let's review the charts and indicators to see what they are showing today.
Possible M&A Surrounds These 3 Stocks
M&A activity has generally slowed.
The Cannabis Sector and Its Dot-Com Like Meltdown
Black-market vaping has made the entire cannabis group toxic.